Loading patent…
AssigneeDignity Health
InventorsRobert Bowser, Mahlon Collins
Estimating the term…
The invention relates to diagnosis, prognosis and treatment of neurological diseases. In one embodiment, the present invention provides methods and kits that diagnose whether a subject has a neurological disease or susceptibility to a neurological disease by evaluating nuclear stress body (NSB) levels. Further described are methods and kits that prognose a neurological disease in a subject by monitoring changes in NSB levels. Also described are methods and kits that treat neurological diseases by administering one or more inhibitors of NSB signaling to a patient, as well as compositions containing one or more NSB signaling inhibitors. Medical conditions suitable with various embodiments of the invention include but are not limited to ALS, FTLD, dementia and AD.
A method for diagnosing whether a subject has neurological disease, comprising:
A kit for diagnosing whether a subject has neurological disease, comprising:
A method for diagnosing whether a subject has susceptibility to neurological disease, comprising:
14-16. (canceled)
A method for prognosing a neurological disease in a subject, comprising:
A method of treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a neurological disease in a subject, comprising:
26-29. (canceled)
(canceled)
A kit for treating, preventing, reducing the likelihood of having, reducing the severity of and/or slowing the progression of a neurological disease in a subject, comprising:
A composition comprising an inhibitor of NSB signaling.
39-42. (canceled)
Dependencies are inferred from the claim text.